Swiss biotech, Numab Therapeutics, has raised $22.6 million in Series B financing to advance a portfolio of novel multi-specific antibodies in immuno-oncology.
New investors included 3SBio/Sunshine Guojian, Mitsubishi UFJ Capital Co, and Eisai Co, as well as Numab’s board member Dr Daniel Vasella.
Existing shareholders that participated in Numab’s Series A round also contributed.
Numab will use the proceeds further broaden its proprietary pipeline and accelerate the development for a number of programs towards the clinic.
The company also plans to initiate a clinical trial for its lead oncology program ND021 during the course of 2020.
Numab and Eisai entered into a global research and option agreement to discover and develop a portfolio of multi-specific antibody immunotherapies for cancer in October 2019. In December 2019, Numab added a regional alliance with 3SBio’s subsidiary Sunshine Guojian Pharmaceutical Co to its growing roster of pharmaceutical partnerships.
Multi-specific antibodies have the potential to unlock entirely novel modes-of-action aiming at superior benefit-to-risk profiles relative to conventional cancer immune therapies.
Numab’s proprietary MATCH technology platform represents one of the most versatile and flexible sources for multi-specific antibodies, the company said.
MATCH molecules can incorporate up to six binding specificities in true plug-and-play fashion. The individual antibody Fv building blocks are designed for maximum stability and developability.